Biomarker for ovarian and endometrial cancer: hepcidin
First Claim
Patent Images
1. A method for qualifying ovarian cancer status in a subject comprising:
- (a) measuring the level of hepcidin in a biological sample from the subject being screened for ovarian cancer; and
(b) correlating the measurement of an increased level of hepcidin in the biological sample from the subject as compared to the level of hepcidin in a biological sample from a healthy subject with the diagnosis of ovarian cancer.
9 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
84 Citations
14 Claims
-
1. A method for qualifying ovarian cancer status in a subject comprising:
- (a) measuring the level of hepcidin in a biological sample from the subject being screened for ovarian cancer; and
(b) correlating the measurement of an increased level of hepcidin in the biological sample from the subject as compared to the level of hepcidin in a biological sample from a healthy subject with the diagnosis of ovarian cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- (a) measuring the level of hepcidin in a biological sample from the subject being screened for ovarian cancer; and
Specification